RCKTW

ROCKET PHARMACEUTICALS INC

• Reuters·04/01 12:48

  FDA: ISSUANCE OF A PRIORITY REVIEW VOUCHER TO THE SPONSOR OF A RARE PEDIATRIC DISEASE PRODUCT APPLICATION- FEDERAL REGISTER WEBSITE

• Reuters·04/01 12:48

  FDA: DETERMINED THAT KRESLADI MEETS THE CRITERIA FOR A PRIORITY REVIEW VOUCHER- FEDERAL REGISTER WEBSITE

• Reuters·03/27 15:48

  BUZZ-U.S. STOCKS ON THE MOVE-Entergy, IDEX Corp, Quanta Services

• Reuters·03/27 13:15

  BUZZ-U.S. STOCKS ON THE MOVE-Alphabet, Phathom, Argan

• Reuters·03/27 12:52

  ROCKET PHARMA EXEC SAYS NOT PROVIDING PRICING GUIDANCE FOR KRESLADI

• Reuters·03/27 12:52

  ROCKET PHARMA EXEC SAYS CO ANTICIPATES COMMERCIAL AVAILABILITY OF KRESLADI IN Q4 OF 2026 - EXEC SAYS

• Reuters·03/27 12:52

  ROCKET PHARMA EXEC SAYS CO HAS BEEN ENGAGING WITH PAYERS TO ENSURE REIMBURSEMENT AHEAD OF LAUNCH - CONF CALL

• Reuters·03/27 12:52

  ROCKET PHARMA EXEC SAYS CO IN ACTIVE DISCUSSIONS AND ENGAGING WITH EXTERNAL PARTIES REGARDING THE SALE OF THE PRIORITY REVIEW VOUCHER

• Reuters·03/27 12:19

  ROCKET PHARMACEUTICALS SHARES UP 10.2% PREMARKET AFTER US FDA APPROVE CO'S THERAPY FOR DEADLY CHILDHOOD DISORDER

• Reuters·03/27 11:52

  BUZZ-Rocket Pharma rises after FDA approves gene therapy for fatal childhood disorder

• Reuters·03/27 11:20

  Rocket Pharma shares climb as FDA approves first therapy for deadly childhood disorder

• Reuters·03/27 11:01

  Rocket Pharmaceuticals gains FDA accelerated approval for KRESLADI in severe pediatric LAD-I; FDA grants rare pediatric disease priority review voucher

• Reuters·03/27 11:00

  ROCKET PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF KRESLADI™ FOR PEDIATRIC PATIENTS WITH SEVERE LEUKOCYTE ADHESION DEFICIENCY-I (LAD-I)

• Reuters·03/25 10:03

  Rocket Pharmaceuticals announces 2026 annual stockholders meeting

• Reuters·03/10 21:35

  ROCKET PHARMACEUTICALS INC - ENTERS SALES AGREEMENT WITH CANTOR FITZGERALD & CO. FOR ATM OFFERING UP TO $100 MLN - SEC FILING